SCHEMBL20746423

SCHEMBL20746423

O=C(O)c1ccnc(N2CCCCC2=O)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.44
▸ HPGD P15428 2/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ GNE Q9Y223 1/20 0.40
▸ KDM4E B2RXH2 2/20 0.39
▸ KDM5A P29375 1/20 0.39
▸ JMJD1C Q15652 1/20 0.39
▸ KDM3A Q9Y4C1 1/20 0.39
▸ RBP4 P02753 2/20 0.37
▸ TTR P02766 1/20 0.36
▸ MAPK8 P45983 1/20 0.36
▸ CDC7 O00311 1/20 0.36
▸ P2RX3 P56373 1/20 0.35
▸ KDM4C Q9H3R0 1/20 0.34
▸ ATR Q13535 1/20 0.34
▸ ATRIP Q8WXE1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22320524 0.84 CRBN (0.50) ALDH1A1HPGDCYP2D6CYP2C19CRBN
SCHEMBL28070878 0.79 MAPK8 (0.52) ALDH1A1HPGDCYP2C19GNEKDM4E
SCHEMBL28087268 0.77 MAPK8 (0.54) ALDH1A1HPGDGNEKDM4EKDM5A
SCHEMBL20745993 0.77 PARP1 (0.35) ALDH1A1HPGDCYP1A2CYP3A4CYP2D6
SCHEMBL14500914 0.72 ALDH1A1 (0.56) ALDH1A1HPGDCYP1A2CYP3A4CYP2D6
SCHEMBL17144056 0.71 ALDH1A1 (0.52) ALDH1A1HPGDCYP1A2CYP3A4CYP2D6
SCHEMBL31205843 0.70 KDM4E (0.52) ALDH1A1HPGDCYP2C19KDM4ELMNA
SCHEMBL16424985 0.70 PANK3 (0.39) ALDH1A1P2RX3IDH1
SCHEMBL4784806 0.69 ALDH1A1 (0.42) ALDH1A1HPGDCYP1A2CYP3A4CYP2D6
SCHEMBL4784801 0.69 ALDH1A1 (0.42) ALDH1A1HPGDCYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112739343-A Macrocyclic MCL-1 inhibitors and methods of use 艾伯维公司 2021-04-30 — — CN disclosed
US-20200255451-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE ABBVIE INC (US) 2020-08-13 — — US disclosed
EP-3668504-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE AbbVie Inc. (US) 2020-06-24 — — EP disclosed
WO-2019035914-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE ABBVIE INC. (US) 2019-02-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200255451-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE MCL1, BCL2A1, BCL2L10 ALDH1A1 647/4885HPGD 4454/4885CYP1A2 2467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback